Huntington’s Disease Market Spotlight Report 2019: 10-Year Disease Prevalence and Drug-Specific Revenue Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Huntington’s Disease” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the Huntington’s disease market,
comprising key marketed and pipeline drugs, clinical trials, upcoming
and regulatory events, recent events and analyst opinion, probability of
success, patent information, a 10-year disease prevalence forecast, and
licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts

Key Takeaways

• The report estimates that in 2017, there were 159,410 prevalent cases
  of Huntington’s disease (HD) in adults aged 30 years and older
  worldwide, and forecasts that number to increase to 184,950 prevalent
  cases by 2026.
• Northern America is estimated to have the highest disease prevalence
  (0.0073%), while Asia has the lowest prevalence (0.0004%).
• Teva’s Austedo and Bausch Health’s Xenazine, which target vesicular
  monamine transporters, are the only marketed drugs for HD. These drugs
  are administered via the oral route.
• The majority of industry-sponsored drugs in active clinical
  development for HD are in Phase II, with only one drug in Phase III.
  Therapies in mid-to-late-stage development for HD focus on targets
  such as lysosomal cysteine transporter, Huntington, SIRT1, vasopressin
  receptors, semaphorin 4D/CD100, aryl hydrocarbon receptor,
  phosphodiesterase 10a, PPAR delta, and PPAR gamma. The majority of the
  pipeline drugs are administered via the oral route, with the remainder
  being intrathecal and intravenous formulations.
• The only high-impact upcoming event in the HD space is topline Phase
  II trial results for VX15. The overall likelihood of approval of a
  Phase I neurodegenerative asset is 7.7%, and the average probability a
  drug advances from Phase III is 48.2%. Drugs, on average, take 10.8
  years from Phase I to approval, compared to 9.6 years in the overall
  neurology space.
• There were 10 licensing and asset acquisition deals involving HD drugs
  during 2014-18. The $1,050m exclusive strategic collaboration and
  option agreement signed in 2018 between AbbVie and Voyager
  Therapeutics for the development and commercialization of vectorized
  antibodies directed against tau for the treatment of Alzheimer’s
  disease and other neurodegenerative diseases was the largest deal
  during the period.
• The distribution of clinical trials across Phase I-IV indicates that
  the majority of trials for HD have been in the early and midphases of
  development, with 74% of trials in Phase I-II, and only 26% in Phase
  III-IV.
• The US has a substantial lead in the number of HD clinical trials
  globally, while the UK leads the major EU markets. Clinical trial
  activity in the HD space is dominated by completed trials. Pfizer has
  the highest number of completed trials for HD, with 12 trials.
• Pfizer leads industry sponsors with the highest number of clinical
  trials for HD, followed by Teva.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

Treatment of chorea

Treatment of parkinsonism

Treatment of behavioral and psychiatric dysfunction

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Nerventra for HD (July 31, 2018)

HTT-ASO for HD (March 1, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Two Neurodegenerative Disease Drugs Secure EMA’s Coveted PRIME
Designation

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Takeda Catches Rising Tide Of Antisense Neuroscience R&D

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/38mfi2

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs